Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Armodafinil in excessive sleepiness associated with OSAHS
NCT00078325Phase 3Completed
- Sponsor
- Cephalon, Inc.
- Start
- Feb 2004
- Primary completion
- Nov 2004
- Modality
- Small Molecules
01
Overview
Phase 3, randomised, double-blind trial of armodafinil in obstructive sleep apnea syndrome (OSAS) (3 arms), sponsored by Cephalon, Inc. Primary endpoints: Maintenance of Wakefulness Test at 12 weeks and Clinical Global Impression of Change at 12 weeks. Started Feb 2004; status: completed.
02
Drugs
armodafinil
03
Conditions
obstructive sleep apnea syndrome (OSAS)
Beyond the preview
Go deeper on NCT00078325.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00078325.